Summit Therapeutics Inc. ranks below the peer group median, with a broadly weak profile — no strong structural dimension across the main areas. The market setup has weakened, with clear trend damage and relative performance under pressure.
Peer-relative scores, weakest to strongest
Summit Therapeutics develops late-stage investigational drugs for cancer treatment. The company currently has no approved products on the market.
The valuation discount reflects fundamental weakness. With an operating margin of 0.0% and one-year volatility at 90.4%, the market prices Summit at a steep discount in direct response to the binary risk of FDA approval—there is no product revenue and losses are significant. Summit is a clinical-stage biotech with no approved product; its valuation depends almost entirely on the outcome of the FDA decision, not on ongoing commercial activity. The market continues to discount the stock due to the absence of an approved product and a proven business model. Without a product, the discount is a verdict, not an opportunity.
Break down SMMT's position across all dimensions with the full interactive tool.
This analysis is rule-based and descriptive. Peer-relative scores are derived from functional peer group comparisons using publicly available financial data. Scores reflect structural positioning only and do not constitute investment advice, a buy or sell recommendation, or a forecast of future performance. AssetNext peer scores are recalculated periodically as new data becomes available.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.